Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way

Moderna Inc MRNA says that it's on its way to having two mRNA vaccines against different seasonal flu viruses.
The Company released the first early data from Phase 1 study of mRNA-1010, announcing that all doses of the shot significantly boosted antibodies in younger and older adults without "significant safety findings."
Moderna said the 50 microgram dose increased antibodies against the two Influenza A strains by eight-fold and ten-fold, respectively, and against the other two influenza strains by three-fold and two-fold.
For now, the investors appear primarily bearish, as they will compare Moderna's data with early results from the ongoing Phase 1 trial from BioNTech SE BNTX and Sanofi SA's SNY Translate Bio Inc in the coming months.
Related Link: Pfizer Joins Influenza Vaccine Race, Kick Starts Early-Stage Trial.
A 500-person Phase 2 dose-confirming study is already enrolled, the Company said, and preparations for a large pivotal trial are underway.
The Phase 2 study of mRNA-1010 was initiated in November to confirm dose across three dose levels, including a lower 25 µg dose level and 50 µg & 100 µg with approximately 150 participants per arm. An interim analysis is expected in early 2022.
Price Action: MRNA shares are down 9.33 at $246.80 during the market session on the last check Friday.